New Molecule Could Slow The Progression Of Parkinson’s
News Feb 27, 2015
In Parkinson’s, a protein called α-synuclein changes shape and stacks with other misshapen proteins. The new molecule binds to the sticky part of α-synuclein, stopping it from clumping and killing brain cells.
Dr Jody Mason, from the Department of Biology & Biochemistry, explained: “If you think of the misshapen α-synuclein proteins as Lego bricks which stack to form a tower; our peptide acts like a smooth brick that sticks to the α-synuclein and stops the tower from growing any bigger.
“This research is in the early stages, but the results so far are very encouraging. We still need to overcome many obstacles before this can be developed into a drug treatment, but these findings could herald a new approach to treating Parkinson’s.”
An incurable disease
Parkinson’s affects around 1 in 500 people in the UK. It’s a progressive neurological condition where brain cells die causing a lack of the chemical dopamine, which acts as a messenger that coordinates movement. Parkinson’s causes symptoms of tremor, rigidity and slowness of movement.
The research team led by Bath designed the 10 amino-acid peptide molecule by screening a library of peptides based on the region of α-synuclein that is mutated in patients with early onset Parkinson’s. This is the first time that this part of the α-synuclein protein has been explored as a potential drug target.
The study, published in the Journal of Biological Chemistry, showed that the molecule stopped α-synuclein clumping in living cells in the lab. The team anticipates that if developed into a treatment, the peptide could help slow the progression of this degenerative disease.
The researchers next hope to test the peptide in mammalian neurone cells and then develop it into a drug that is effective in humans.
“We need more successes, like this one"
Co-author Dr Neil Kad, from the University of Kent, added: “This Parkinson’s UK funded work shows how investment in basic science can open up new ways of studying and ultimately treating neurodegenerative disease.”
Dr Arthur Roach, Director of Research and Development at Parkinson’s UK, which funded the study, said: “It’s a difficult task to develop treatments that can stop the toxic build-up of proteins in the brains of people with Parkinson’s. Supporting this kind of innovative research approach is starting to make imaginable today what seemed impossible a decade ago.
“We need more successes, like this one, if we are to develop drugs that could actually slow or stop the progression of Parkinson’s. At the moment no drugs are capable of doing this.”
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE